These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 17414400)

  • 1. New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 months.
    Wong S; Lennon D; Jackson C; Stewart J; Reid S; Crengle S; Tilman S; Aaberge I; O'Hallahan J; Oster P; Mulholland K; Martin D
    Pediatr Infect Dis J; 2007 Apr; 26(4):345-50. PubMed ID: 17414400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II meningococcal B vesicle vaccine trial in New Zealand infants.
    Jackson C; Lennon DR; Sotutu VT; Yan J; Stewart JM; Reid S; Crengle S; Oster P; Ypma E; Aaberge I; Mulholland K; Martin DR
    Arch Dis Child; 2009 Oct; 94(10):745-51. PubMed ID: 18838420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
    Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
    Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens.
    Hosking J; Rasanathan K; Mow FC; Jackson C; Martin D; O'Hallahan J; Oster P; Ypma E; Reid S; Aaberge I; Crengle S; Stewart J; Lennon D
    Clin Vaccine Immunol; 2007 Nov; 14(11):1393-9. PubMed ID: 17898183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control.
    Thornton V; Lennon D; Rasanathan K; O'Hallahan J; Oster P; Stewart J; Tilman S; Aaberge I; Feiring B; Nokleby H; Rosenqvist E; White K; Reid S; Mulholland K; Wakefield MJ; Martin D
    Vaccine; 2006 Feb; 24(9):1395-400. PubMed ID: 16242221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain.
    Oster P; Lennon D; O'Hallahan J; Mulholland K; Reid S; Martin D
    Vaccine; 2005 Mar; 23(17-18):2191-6. PubMed ID: 15755593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease.
    Nøkleby H; Aavitsland P; O'Hallahan J; Feiring B; Tilman S; Oster P
    Vaccine; 2007 Apr; 25(16):3080-4. PubMed ID: 17287053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand.
    Oster P; O'Hallahan J; Aaberge I; Tilman S; Ypma E; Martin D
    Vaccine; 2007 Apr; 25(16):3075-9. PubMed ID: 17289223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
    Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
    Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.
    Jackson C; Lennon D; Wong S; Yan J; Stewart J; Reid S; Oster P; Ypma E; Martin D
    Arch Dis Child; 2011 Aug; 96(8):744-51. PubMed ID: 21596727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6835; author reply 6835-6. PubMed ID: 17875437
    [No Abstract]   [Full Text] [Related]  

  • 15. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The strategy to control New Zealand's epidemic of group B meningococcal disease.
    O'Hallahan J; Lennon D; Oster P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
    Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
    Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines.
    Sandbu S; Feiring B; Oster P; Helland OS; Bakke HS; Naess LM; Aase A; Aaberge IS; Kristoffersen AC; Rydland KM; Tilman S; Nøkleby H; Rosenqvist E
    Clin Vaccine Immunol; 2007 Sep; 14(9):1062-9. PubMed ID: 17634513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.
    Snape MD; Dawson T; Oster P; Evans A; John TM; Ohene-Kena B; Findlow J; Yu LM; Borrow R; Ypma E; Toneatto D; Pollard AJ
    Pediatr Infect Dis J; 2010 Nov; 29(11):e71-9. PubMed ID: 20844462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
    Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
    Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.